Particularly, it has been found that EVs isolated either from the ER-positive BT474 cell line overexpressing HER2 or in breast cancer patients’ serum can directly bind to the anti-HER2 monoclonal antibody trastuzumab and reduce its bioavailability [82]. This evidence concerns the gene ERBB2 and breast carcinoma.